51
Participants
Start Date
October 31, 2012
Primary Completion Date
December 31, 2016
Study Completion Date
December 31, 2017
Reparixin
Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.The Investigational Product (IP) were to be administered as an add-on treatment for the immunosuppressant regimen.
Placebo
Continuous infusion at a volume/rate matching active treatment.The placebo was to be administered as well as an add-on treatment for the immunosuppressant regimen.
Institute for Clinical and Experimental Medicine (IKEM), Diabetes Centre; Department of Diabetes., Prague
Department of Transplantation Surgery; The Karolinska University Hospital, Stockholm
Dipartimento di Medicina Interna e Specialistica; IRCCS Ospedale San Raffaele, Milan
S.S.D. Diabetologia, Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Piazza Ospedale Maggiore 3, Milan
Department of Nephrology and Transplantation; Skane University Hospital, Malmo
Transplant Institute - Sahlgrenska University Hospital, Gothenburg
The University of Chicago Medical Center, Department of Surgery, Division of Abdominal Organ Transplantation, Chicago
Division for Transplantation and Liver Surgery; Department of Surgery; Uppsala University Hospital, Uppsala
Institute of Transplantation, Newcastle upon Tyne Hospitals - NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne
Dompé Farmaceutici S.p.A
INDUSTRY